ArticleNature medicine2022

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.

Julie Westerlin Kjeldsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.